Evidence map›Paper›PMID 29713961›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2018

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.

Michal Witkowski, Lars Wilkinson, Neil Webb, Alan Weids, Divina Glah, Hrvoje Vrazic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Brain Amylin Signaling, Feeding, and Reward.Comprehensive Physiology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Safety of Semaglutide.Frontiers in endocrinology · 2021 · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Michal WitkowskiDRG Abacus, Bicester, Oxfordshire, UK.
Lars WilkinsonNovo Nordisk A/S, Søborg, Denmark.
Neil WebbDRG Abacus, Bicester, Oxfordshire, UK. nwebb@teamdrg.com.
Alan WeidsDRG Abacus, Bicester, Oxfordshire, UK.
Divina GlahNovo Nordisk Ltd., Gatwick, UK.
Hrvoje VrazicNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0000-0001-8151-9899
Novo Nordisk (Denmark) · DKNovo Nordisk (United Kingdom) · GBOxfordshire Clinical Commissioning Group · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnce-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other GLP-1 receptor agonists (GLP-1 RAs) is available. The aim of this study was to conduct a network meta-analysis (NMA) to assess the efficacy and safety of once-weekly semaglutide vs other GLP-1 RAs in patients with T2D inadequately controlled on basal insulin.

methodsA systematic literature review was performed to identify all trials of GLP-1 RAs as an add-on to basal insulin in patients with T2D. Data at 24 ± 4 weeks were extracted for efficacy and safety outcomes (feasible for analysis in an NMA), including the change from baseline in glycated hemoglobin (HbA

resultsIn total, eight studies were included across the base-case analyses. The results demonstrate that once-weekly semaglutide 1.0 mg was associated with significantly greater reductions in HbA

conclusionOnce-weekly semaglutide 1.0 mg as an add-on to basal insulin is likely to be the most efficacious GLP-1 RA for reducing HbA

fundingNovo Nordisk.

Indexed as

Basal insulinGLP-1 receptor agonistGlycemic controlHbA1cNetwork meta-analysisSemaglutideSystematic reviewSystolic blood pressureType 2 diabetesWeight

Identifiers

PMID29713961
PMCPMC5984931
OpenAlexW2799276912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.